Asim Shah, MD
Psychiatry · Houston, TXNPI 1275525834
Payments from drug & device makers
Across 480 payments — averaging $4521.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$443K
- Alkermes, Inc.$377K
- Janssen Research & Development, LLC$356K
- Acadia Pharmaceuticals Inc$231K
- Neurocrine Biosciences, Inc.$214K
- Supernus Pharmaceuticals, Inc.$148K
- plus $402K from 6 others
Across 8 payments — averaging $224.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$2K
- Supernus Pharmaceuticals, Inc.$202
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 17 | $443,239 |
| Alkermes, Inc. | 192 | $376,523 |
| Janssen Research & Development, LLC | 42 | $355,910 |
| Acadia Pharmaceuticals Inc | 22 | $230,686 |
| Neurocrine Biosciences, Inc. | 104 | $213,884 |
| Supernus Pharmaceuticals, Inc. | 29 | $148,192 |
| Hoffmann-la Roche Limited | 27 | $134,035 |
| Avanir Pharmaceuticals, Inc. | 20 | $95,530 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75,271 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $56,325 |
| Corcept Therapeutics | 9 | $31,224 |
| Boehringer Ingelheim RCV GmbH & Co KG | 11 | $9,658 |
How this compares
$2,170,476 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Rayan Al JurdiHouston$712K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.